糖尿病患者中的苯乙双胍；临床及代谢效应
Phenethylbiguanide in diabetic patients; clinical and metabolic effects.
作者信息
LAMBERT T H
出版信息
Calif Med. 1959 Apr;90(4):257-60.
Phenethylbiguanide (DBI) was given to 70 unselected but not obese diabetic patients who were receiving restricted diabetic diets. The only side effects attributed to the drug were anorexia, nausea, vomiting and diarrhea in 28 patients. These symptoms subsided with reduction of dosage. No evidence of serious toxicity has been demonstrated in clinical and metabolic studies. In 27 of the 70 patients diabetes was controlled adequately with DBI alone, and more stable control was obtained in 11 labile diabetics who received DBI in combination with insulin.The mechanism of action is not definitely known.
将苯乙双胍（DBI）给予70名未经过挑选但非肥胖的糖尿病患者，这些患者正在接受限定的糖尿病饮食。唯一归因于该药物的副作用是28名患者出现厌食、恶心、呕吐和腹泻。这些症状随着剂量的减少而消退。临床和代谢研究中未显示出严重毒性的证据。在70名患者中，27名仅使用DBI就能充分控制糖尿病，11名不稳定型糖尿病患者联合使用DBI和胰岛素后获得了更稳定的控制。作用机制尚不完全清楚。
Zotero 插件